About: Invasive Group A Streptococcal Disease: Epidemiology, Pathogenesis and Management

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Invasive Group A Streptococcal Disease: Epidemiology, Pathogenesis and Management Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Invasive Group A Streptococcal Disease: Epidemiology, Pathogenesis and Management
Creator	Curtis, Nigel Carapetis, Jonathan Steer, Andrew Lamagni, Theresa
Source	PMC
abstract	Invasive group A streptococcal infections are uncommon, although serious, infections with high case fatality rates. Periodic resurgences in invasive group A streptococcal infections in industrialized countries have been reported from the 1980s onwards, with current estimates of incidence in these countries of approximately 3–4 per 100000 population. Infants, pregnant women and the elderly are at increased risk of invasive group A streptococcal infection. The group A streptococcus has an array of virulence factors that underpin its invasive capacity and, in approximately 10% of cases, super-antigen toxins produced by the bacteria stimulate a large proportion of T cells, leading to streptococcal toxic shock syndrome. Given the rapid clinical progression, effective management of invasive group A streptococcal infections hinges on early recognition of the disease and prompt initiation of supportive care (often intensive care) together with antibacterial therapy. In cases of toxic shock syndrome, it is often difficult to distinguish between streptococcal and staphylococcal infection before cultures become available and so antibacterial choice must include coverage of both of these organisms. In addition, clindamycin is an important adjunctive antibacterial because of its anti-toxin effects and excellent tissue penetration. Early institution of intravenous immunoglobulin therapy should be considered in cases of toxic shock syndrome and severe invasive infection, including necrotizing fasciitis. Early surgical debridement of necrotic tissue is also an important part of management in cases of necrotizing fasciitis.
has issue date	2012-01-06(xsd:dateTime)
bibo:doi	10.2165/11634180-000000000-00000
bibo:pmid	22686614
has license	no-cc
sha1sum (hex)	b0b143517a295247472accdf733f36ffa63bfb99
schema:url	https://doi.org/10.2165/11634180-000000000-00000
resource representing a document's title	Invasive Group A Streptococcal Disease: Epidemiology, Pathogenesis and Management
has PubMed Central identifier	PMC7100837
has PubMed identifier	22686614
schema:publication	Drugs
resource representing a document's body	covid:b0b143517a295247472accdf733f36ffa63bfb99#body_text
is schema:about of	named entity 'Streptococcal' named entity 'pharyngeal infection' named entity 'genital tract' named entity 'antibacterial' named entity 'epithelial cells' named entity 'GAS' named entity 'margin of error' named entity 'intensive care' named entity 'selection bias' named entity 'Surgical management' named entity 'STSS' named entity 'GAS' named entity 'necrotic tissue' named entity 'Penicillin' named entity 'living conditions' named entity 'infection' named entity 'infection' named entity 'GAS' named entity 'randomized controlled trial' named entity 'infection' named entity 'Gram-negative bacteria' named entity 'GAS' named entity 'GAS' named entity 'clindamycin' named entity 'developing countries' named entity 'impetigo' named entity 'rash' named entity 'GAS' named entity 'debridement' named entity 'Skin lesions' named entity 'Streptococcal' named entity 'rash' named entity 'sepsis' named entity 'cytokines' named entity 'IVIG' named entity 'vasodilation' named entity 'prophylaxis' named entity 'scarlet fever' named entity 'hypotension' named entity 'sepsis' named entity '3.5' named entity 'Superantigens' named entity 'fever' named entity 'cell surface proteins' named entity 'infection' named entity 'tissue necrosis' named entity 'Superantigens' named entity 'empiric treatment' named entity 'STSS' named entity 'clindamycin' named entity 'STSS' named entity 'STSS' named entity 'epidemiological studies' named entity 'pathogenicity' named entity 'STSS' named entity 'Diagnostic criteria' named entity 'postpartum period' named entity 'NSAIDs' named entity 'Prague' named entity 'Morbidity and mortality' named entity 'STSS' named entity 'pleural empyema' named entity 'virulent' named entity 'industrialized countries' named entity 'neutrophils' named entity 'fever' named entity 'Randomized controlled trial' named entity 'GAS' named entity 'septic arthritis' named entity 'varicella infection' named entity 'tumour necrosis factor' named entity 'STSS' named entity 'elderly patients' named entity 'toxic shock syndrome' named entity 'bullae' named entity 'magnetic resonance imaging' named entity 'adult respiratory distress syndrome' named entity 'antibacterial'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software